BLAINJECTIONINJECTABLE
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VYEPTI (eptinezumab-jjmr) by Lundbeck is calcitonin gene-related peptide antagonists [moa]. First approved in 2020.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYEPTI (eptinezumab-jjmr) is a monoclonal antibody that antagonizes calcitonin gene-related peptide (CGRP), a key mediator of migraine pathophysiology. Administered as an intravenous injection, it is indicated for migraine prevention in adult patients. The drug works by blocking CGRP signaling, reducing the frequency and severity of migraine episodes.
$9MPart D
PeakVYEPTI is in peak commercial phase with modest Medicare utilization, indicating a mature but competitive market requiring targeted medical and sales strategies.
Mechanism of Action
Calcitonin Gene-related Peptide Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VYEPTI offers stability in a mature, peak-stage product with strong clinical validation but moderate commercial momentum. Roles focus on defending market position, optimizing payer relationships, and educating healthcare providers on IV administration advantages.
Brand ManagerMedical Science Liaison
Worked on VYEPTI at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.